Dianthus Therapeutics, Inc.
Status: Publicly traded
Direct answer
Dianthus Therapeutics, Inc. is publicly traded on NASDAQ under the ticker DNTH.
Dianthus Therapeutics, Inc. is a clinical-phase biotechnology firm dedicated to conceiving, developing, and providing cutting-edge monoclonal antibody treatments. These therapies are intended for individuals grappling with serious autoimmune and inflammatory conditions. The company's pipeline includes DNTH103, an investigational drug presently undergoing Phase 1 clinical assessment in patients diagnosed with...
Can you invest in Dianthus Therapeutics, Inc.?
Yes. Dianthus Therapeutics, Inc. is publicly traded on NASDAQ under the ticker DNTH.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Dianthus Therapeutics, Inc.
Detailed equity research is provided by MarketSnap.